Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to establish the role of neoadjuvant chemotherapy and chemo irradiation in carcinoma cervix and to compare its results with the concurrent chemo irradiation in terms of overall survival, disease free survival and quality of life.
Early stage bulky cancers of the cervix, (defined as FIGO Stages IB2, IIA2 and IIB) form a distinctive subset of "curable" cervical cancers with good 5 year survival rates with adequate treatment. Concurrent chemo radiation with or without salvage surgery is at present the standard of care for this group of cervical cancers. However, when pelvic recurrences occur, the morbidity of salvage surgery after radiotherapy, especially brachytherapy is often higher than the morbidity of salvage radiotherapy following radical surgery. The advantages of downsizing the disease without the use of brachytherapy are tempting and open a completely new philosophy in radical treatment for "curable" early stage bulky cancers of the cervix. This approach is appealing especially in developing countries where the load of cervical cancers is high and radiotherapy (brachytherapy) resources are scarce.
The results of two Phase II trials conducted at Govt. Royapettah Hospital, Chennai (Neoadjuvant Chemotherapy followed by Radical Hysterectomy: Cisplatin + 5FU vs. Cisplatin +Paclitaxel) and at Govt. General Hospital,Chennai (Neoadjuvant Chemoradiation with weekly cisplatin and 50 EBRT followed by radical Hysterectomy) and one retrospective study ( Preoperative 50 GY EBRT followed by Radical Hysterectomy) have shown similar response rates and acceptable toxicity profiles when compared to concurrent chemoradiation (EBRT + Brachytherapy+ Chemotherapy). Similar studies have been published elsewhere with similar results.
With this in mind we are planning to conduct a Phase III Randomised control trial comparing Neoadjuvant Chemotherapy + Radical Hysterectomy and Neoadjuvant Chemoradiation + Radical Hysterectomy with concurrent chemoradiation in this subset of cervical cancers
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Concurrent Radical Chemoradiation | Active Comparator | Paclitaxel(175 mg/sq.m) + Cisplatin (75 mg/sq.m) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT + Brachytherapy (7Gy HDR x 3 doses) All to be completed within 8-10 weeks |
|
| Neoadjuvant Chemoradiation + Radical Hysterectomy | Experimental | Paclitaxel(175 mg/m2) + Cisplatin(75 mg/m2) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT - completed within 5 weeks Radical Hysterectomy - 3 weeks after completion of RT All to be completed within 8-10 weeks |
|
| Neoadjuvant Chemotherapy + Radical Hysterectomy | Experimental | Paclitaxel(175 mg/m2) + Cisplatin (75 mg/m2) chemotherapy - 3 cycles of 3 weekly cycle Radical Hysterectomy - 3 weeks after completion of chemotherapy All to be completed within 8-10 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Chemotherapy | Drug | cisplatin 75 mg/m2 Paclitaxel 175 mg/m2 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall and Disease free Survival | 3 year | |
| Overall and Disease free Survival | 5 year |
| Measure | Description | Time Frame |
|---|---|---|
| Acute Adverse reactions and complications | Less than 10 weeks | |
| SubAcute Adverse reactions and complications | 10 weeks - 6 months | |
| Chronic Adverse reactions and complications |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life | 3,5 years |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Rajaraman Ramamurthy, MS MCh | Contact | +919444046168 | rajaanu1@rediffmail.com | |
| Subbiah Shanmugam, Ms MCh | Contact | +919360206030 | subbiah_doctor@yahoo.co.uk |
| Name | Affiliation | Role |
|---|---|---|
| Rajaraman Ramamurthy, MS MCh | centre for oncology, Government Royapettah Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Government Royapettah Hospital | Recruiting | Chennai | Tamil Nadu | 600014IndiaNaduI6 | India |
Not provided
| ID | Term |
|---|---|
| D002583 | Uterine Cervical Neoplasms |
| ID | Term |
|---|---|
| D014594 | Uterine Neoplasms |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
| ID | Term |
|---|---|
| D004358 | Drug Therapy |
| D001918 | Brachytherapy |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
| D011878 | Radiotherapy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| External Beam Radiotherapy | Radiation | 50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5 |
|
| Brachytherapy | Radiation | Ir - 192 HDR Brachytherapy - intracavitary. 7Gy x 3#. given after completion of chemoRT. |
|
| Radical Hysterectomy | Procedure | Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection |
|
| 6 months to 5 years |
| D009369 |
| Neoplasms |
| D002577 | Uterine Cervical Diseases |
| D014591 | Uterine Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |